Zogenix (NASDAQ: ZGNX)‘s stock had its “outperform” rating restated by equities researchers at Leerink Swann in a report issued on Wednesday.
Shares of Zogenix opened at 1.21 on Wednesday. Zogenix has a 52 week low of $1.11 and a 52 week high of $3.30. The stock’s 50-day moving average is currently $1.41. The company’s market cap is $121.8 million.
ZGNX has been the subject of a number of other recent research reports. Analysts at Stifel Nicolaus downgraded shares of Zogenix from a “buy” rating to a “hold” rating in a research note to investors on Monday, December 10th. They now have a $6.00 price target on the stock. Separately, analysts at Wells Fargo reiterated an “outperform” rating on shares of Zogenix in a research note to investors on Monday, December 10th. Finally, analysts at Oppenheimer downgraded shares of Zogenix from an “outperform” rating to a “perform” rating in a research note to investors on Monday, December 10th. They now have a $3.00 price target on the stock.
Three research analysts have rated the stock with a buy rating, and two have issued a hold rating to the company’s stock. The company currently has an average rating of “overweight” and a consensus price target of $3.00.
Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
